Last reviewed · How we verify
AGN-199201 Dose C
AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect.
AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect. Used for Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported..
At a glance
| Generic name | AGN-199201 Dose C |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of AGN-199201 Dose C is not well understood, but it is believed to work by interacting with the molecular target to produce a therapeutic effect.
Approved indications
- Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported.
Common side effects
- Unknown
Key clinical trials
- A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
- A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
- AGN-199201 for the Treatment of Erythema With Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-199201 Dose C CI brief — competitive landscape report
- AGN-199201 Dose C updates RSS · CI watch RSS
- Allergan portfolio CI